In WD-fed mice undergoing myocardial IRI surgery, Oleuropein pretreatment significantly reduced infarct size compared to the respective vehicle group. In HFD-fed male mice receiving Oleuropein, food intake was 17.0 ± 0.1 g/week, with HFD as the control. In WD-fed mice, Oleuropein significantly decreased fasting glucose levels at 14 weeks compared to the Vehicle (NS) group. [2,3]
Reduced infarct size in WD-fed mice
Animal study · C57Bl6 mice were fed with WD for 14 weeks to induce MS; OL 20.6 mg/kg (n = 7) [2]
In WD-fed mice undergoing myocardial IRI surgery, Oleuropein pretreatment at 20.6 mg/kg by oral gavage significantly reduced infarct size compared to the respective vehicle group.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- for the last 6 weeks daily
- Vehicle
- sterile normal saline (NaCl 0.9 %)
- Oleuropein 20.6 mg/kg
- Model: C57Bl6 mice were fed with WD for 14 weeks to induce MS; OL 20.6 mg/kg (n = 7)
Methods and source locations
Compound reported in the paper: Oleuropein
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Compounds isolation, purification and identification (S17); Materials and methods > In vivo experimental protocols > 2ndseries of experiments: Investigation of OL, HT, OC and OA effects on myocardial IRI in the presence of MS (S40, S41, S42, S43, S50); Materials and methods > Infarct size measurement after IRI (S91, S93, S94); Results > Chronic pretreatment with OL, OC and OA at nutritional dose reduces myocardial infarct size in healthy and MS-burdened mice (S192); Fi...
infarct size: infarct size; comparator: Vehicle NS (n = 6) — Materials and methods > In vivo experimental protocols > 2ndseries of experiments: Investigation of OL, HT, OC and OA effects on myocardial IRI in the presence of MS (S50); Results > Chronic pretreatment with OL, OC and OA at nutritional dose reduces myocardial infarct size in healthy and MS-burdened mice (S192)
Oleuropein 20.6 mg/kg · Materials and methods > In vivo experimental protocols > 2ndseries of experiments: Investigation of OL, HT, OC and OA effects on myocardial IRI in the presence of MS (S41, S43); Results > Chronic pretreatment with OL, OC and OA at nutritional dose reduces myocardial infarct size in healthy and MS-burdened mice (S192)
Food intake in HFD-fed mice
Animal study · Five-week-old male C57BL/6JOlaHsd mice; HFD-OLE, n = 4 [3]
HFD-fed male mice received Oleuropein at 20 mg/kg by daily oral gavage for 5 weeks, with HFD as the control. Food intake in the treated group was 17.0 ± 0.1 g/week.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- daily; for 5 weeks
- Oleuropein 20 mg/kg
- Model: Five-week-old male C57BL/6JOlaHsd mice; HFD-OLE, n = 4
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Oleuropein
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Animals and Study Design (S8, S12); Table 1 legend (S90); Table 1 (T1.h1, T1.r1)
Food intake (g/week): Food intake (g/week); comparator: HFD — Table 1 (T1.h1, T1.r1)
Oleuropein 20 mg/kg · Materials and Methods > Animals and Study Design (S12); Table 1 (T1.h1, T1.r1)
Decreased fasting glucose in WD-fed mice
Animal study · C57Bl6 mice were fed with WD for 14 weeks to induce MS; OL 20.6 mg/kg (n = 7) [2]
WD-fed mice received Oleuropein at 20.6 mg/kg by daily oral gavage during the last 6 weeks. Treatment significantly decreased fasting glucose levels at 14 weeks compared to the Vehicle (NS) group.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- for the last 6 weeks daily
- Vehicle
- sterile normal saline (NaCl 0.9 %)
- Oleuropein 20.6 mg/kg
- Model: C57Bl6 mice were fed with WD for 14 weeks to induce MS; OL 20.6 mg/kg (n = 7)
Methods and source locations
Compound reported in the paper: Oleuropein
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Compounds isolation, purification and identification (S17); Materials and methods > In vivo experimental protocols > 2ndseries of experiments: Investigation of OL, HT, OC and OA effects on myocardial IRI in the presence of MS (S40, S41, S42, S43); Results > OL mitigated hyperglycemia and increased insulin levels in plasma (S195); Fig. 2 legend (S285)
fasting glucose levels at 14 weeks: fasting glucose levels at 14 weeks; comparator: Vehicle NS (n = 6) — Results > OL mitigated hyperglycemia and increased insulin levels in plasma (S195)
Oleuropein 20.6 mg/kg · Materials and methods > In vivo experimental protocols > 2ndseries of experiments: Investigation of OL, HT, OC and OA effects on myocardial IRI in the presence of MS (S41, S43); Results > OL mitigated hyperglycemia and increased insulin levels in plasma (S195)